2, 5% af nyligt diagnosticerede CML- patienter i behandling med Glivec er der rapporteret tilfælde af svær væskeretention (pleuraeksudat, ødem, pulmonært ødem, ascites, perifert ødem).
Occurrences of severe fluid retention (pleural effusion, oedema, pulmonary oedema, ascites, superficial oedema) have been reported in approximately 2.5% of newly diagnosed CML patients taking Glivec.